

# A multicopy suppressor of a cell cycle defect in *S.pombe* encodes a heat shock-inducible 40 kDa cyclophilin-like protein

Ronit Weisman<sup>1</sup>, James Creanor<sup>2</sup> and Peter Fantès<sup>3</sup>

Institute of Cell and Molecular Biology and <sup>2</sup>Institute of Cell, Animal and Population Biology, University of Edinburgh, Mayfield Road, Edinburgh EH9 3JR, UK

<sup>1</sup>Present address: Department of Molecular Microbiology, University of Tel-Aviv, Tel-Aviv 69978, Israel

<sup>3</sup>Corresponding author

Communicated by A.Bird

**Cyclophilins are peptidyl-prolyl *cis*–*trans* isomerases (PPIases) which have been implicated in intracellular protein folding, transport and assembly. Cyclophilins are also known as the intracellular receptors for the immunosuppressive drug cyclosporin A (CsA). The most common type of cyclophilins are the 18 kDa cytosolic proteins containing only the highly conserved core domain for PPIase and CsA binding activities. The *wis2*<sup>+</sup> gene of the fission yeast *Schizosaccharomyces pombe* was isolated as a multicopy suppressor of *wee1-50 cdc25-22 win1-1*, a triple mutant strain which exhibits a cell cycle defect phenotype. Sequence analysis of *wis2*<sup>+</sup> reveals that it encodes a 40 kDa cyclophilin-like protein, homologous to the mammalian cyclophilin 40. The 18 kDa cyclophilin domain (Cyp-18) of *wis2* is followed by a C-terminal region of 188 amino acids. The C-terminal region of *wis2* is essential for suppression of the triple mutant defect. Furthermore, this region of the protein is able to confer suppression activity on the 18 kDa *S.pombe* cyclophilin, *cyp1*, since a hybrid protein consisting of an 18 kDa *S.pombe* cyclophilin (*cyp1*) fused to the C-terminus of *wis2* shows suppression activity. We also demonstrate that the level of *wis2*<sup>+</sup> mRNA increases 10- to 20-fold upon heat shock of *S.pombe* cells, suggesting a role for *wis2*<sup>+</sup> in the heat-shock response.**

**Keywords:** cell cycle/cyclophilin/fission yeast/heat shock/*S.pombe*

## Introduction

Cyclophilins form a ubiquitous and highly conserved group of proteins, found in all prokaryotic and eukaryotic cells investigated. The first cyclophilin discovered was a cytosolic 18 kDa bovine protein which displayed strong binding affinity to the immunosuppressive drug cyclosporin A (CsA; Handschumacher *et al.*, 1984). This protein was later shown to be identical to a previously identified peptidyl-prolyl *cis*–*trans* isomerase (PPIase; Fischer *et al.*, 1989; Takahashi *et al.*, 1989).

*In vitro*, cyclophilins accelerate rate-limiting *cis*–*trans* peptidyl-prolyl isomerization steps in the folding pathway

of peptide and protein substrates (Lang *et al.*, 1987; Takahashi *et al.*, 1989). It has also been suggested that, in addition to the isomerase activity, cyclophilins affect the yield and kinetics of protein folding *in vitro* by preventing the aggregation of early folding intermediates of protein substrates (Freskgard *et al.*, 1992). The data on cyclophilin function *in vivo* is fragmentary, but several studies have implicated cyclophilins in protein folding, transport and assembly (reviewed in Stammen *et al.*, 1992; Galat, 1993). The best example of this is the photoreceptor-specific *Drosophila melanogaster* cyclophilin, *ninaA*, which is essential for the proper folding and intracellular transport of the photopigment rhodopsin, Rh1 (Ondek *et al.*, 1992). In support of a chaperone function for *ninaA* is the recent finding that it forms a stable complex with Rh1, and that maturation of Rh1 is dependent on the levels of *ninaA* (Baker *et al.*, 1994). Another line of investigation which lends support to the function of cyclophilins as molecular chaperones is the finding that the levels of mRNA of several members of this family, are increased upon heat shock (Sykes *et al.*, 1993; Luan *et al.*, 1994). Disruption of either of the *Saccharomyces cerevisiae* cyclophilin genes *CYP1* or *CYP2* reduces cell survival following exposure to high temperature, providing further evidence for a functional role of cyclophilins during heat shock (Sykes *et al.*, 1993).

Cyclophilins share the property of PPIase activity with another, structurally unrelated family of proteins, the FKBP, which have strong binding affinity to the immunosuppressive agent FK506 (reviewed in Galat, 1993). Collectively, cyclophilins and FKBP are known as immunophilins. When bound to its cognate drug, the PPIase activity of the immunophilin is abolished, but loss of PPIase activity does not appear to be responsible for the immunosuppression effect of the drugs. Rather, the mechanism of action of CsA and FK506 involves the formation of CsA–cyclophilin and FKBP–FK506 complexes, which inhibit the activity of the Ca<sup>2+</sup>/calmodulin-dependent phosphatase calcineurin. The inhibition of calcineurin activity is thought to disrupt the T-cell receptor signal transduction pathway, which normally leads to cytokine gene transcription (Friedman and Weissman, 1991; Liu *et al.*, 1991a; Clipstone and Crabtree, 1992). The immunophilin–drug complexes also block Ca<sup>2+</sup>-dependent signal transduction pathways in yeast (Foor *et al.*, 1992) and plant cells (Luan *et al.*, 1993). First it was thought that neither cyclophilins nor FKBP bind calcineurin in the absence of the cognate drug (Liu *et al.*, 1991a). However, more recent research (Cardenas *et al.*, 1994) has demonstrated physical interaction between the *S.cerevisiae* immunophilin FKBP12 and calcineurin, and between cyclophilin A and calcineurin, in the absence of FK506 and CsA respectively. Moreover, genetic analysis in *S.cerevisiae* demonstrated related phenotypes of calcineurin,

FKBP12 and cyclophilin A. For example, calcineurin mutations prevented recovery from pheromone arrest and conferred hypersensitivity to LiCl, whereas FKBP12 mutants increased recovery from pheromone arrest and enhanced LiCl resistance, suggesting that FKBP12 normally acts to inhibit calcineurin (Cardenas *et al.*, 1994).

The family of cyclophilins has been expanding rapidly, revealing a high degree of sequence conservation across the 18 kDa domain containing the PPIase and CsA binding activity (CyP-18 domain), compared with the diversity of flanking amino acid sequences (Stamnes *et al.*, 1992). Short amino acid extensions at the N- and C-termini of the CyP-18 domain have been shown to play a role in targeting cyclophilins to their specific subcellular localization, such as the endoplasmic reticulum or the mitochondria (reviewed in Galat, 1993). Several proteins have also been identified that contain a CyP-18 domain in addition to other functional regions (Anderson *et al.*, 1993; Galat, 1993).


Here we describe a tentative link between cyclophilin function and the cell cycle. We have been characterizing the *Schizosaccharomyces pombe wis1<sup>+</sup>-wis5<sup>+</sup>* genes which were isolated as multicopy suppressors of the cell cycle defect of the strain *wee1-50 cdc25-22 win1-1* (Warbrick and Fantes, 1992). The *wee1* and *cdc25* proteins are negative and positive regulators, respectively, of the *cdc2* protein kinase, the universal key regulator of entry into mitosis (reviewed in Nurse, 1990). The activity of *cdc2* at the G<sub>2</sub>-mitosis transition is regulated by binding to a regulatory mitotic cyclin (encoded in *S.pombe* by the *cdc13<sup>+</sup>* gene) and by reversible phosphorylation (Gould and Nurse, 1989; reviewed in Nurse, 1990). The *cdc25<sup>+</sup>* gene product of *S.pombe* is a protein tyrosine phosphatase which dephosphorylates *cdc2* on Tyr15, thereby activating the *cdc2* kinase activity (Moreno *et al.*, 1989; Millar *et al.*, 1991). The *wee1<sup>+</sup>* gene product is a protein kinase which phosphorylates *cdc2* on Tyr15, thereby rendering *cdc2* inactive (Featherstone and Russell, 1990; Parker *et al.*, 1991). The *win1<sup>+</sup>* gene has been implicated in regulating entry into mitosis on the basis of genetic interactions (Ogden and Fantes, 1986).

We report here the sequence analysis and preliminary characterization of the *wis2<sup>+</sup>* gene and its protein product. Sequence analysis of *wis2<sup>+</sup>* predicts a 40 kDa protein product with significant sequence similarity to the cyclophilins. The 18 kDa cyclophilin domain lies at the N-terminus and is followed by a C-terminal region of 188 amino acids. We report a structure-function analysis of *wis2<sup>+</sup>*, employing its suppression of the cell cycle defect of *wee1-50 cdc25-22 win1-1* as the *in vivo* test. We also demonstrate that the *wis2<sup>+</sup>* mRNA level is increased upon heat shock, suggesting a role for *wis2* in conditions of elevated temperature.

## Results

### Nucleotide sequence of *wis2<sup>+</sup>*

The plasmid *pwis2-3* was isolated from a gene library as a multicopy suppressor of the conditional lethal phenotype of *wee1-50 cdc25-22 win1-1* (Warbrick and Fantes, 1992). *wee1-50 cdc25-22 win1-1* exhibits a conditional lethal phenotype when grown on minimal medium at the restrictive temperature of 35°C. Under such conditions, the majority of the triple mutant cells are highly elongated, a



**Fig. 1.** Restriction map and activity of subclones. Restriction sites within the insert of *plwis2-1* are indicated on the top bar. The predicted open reading frame is indicated by an arrow. *plwis2-1* and *plwis2-2* are clones in *pIRT2*, *pRwis2* is a clone in *pREP1*. *pSC2-2* is a clone in *pDB248* (Warbrick and Fantes, 1992). +/- indicates suppression of the lethal phenotype of *cdc25-22 wee1-50 win1-1* on minimal medium at 35°C. The suppression activity of *pRwis2* was tested under derepressing conditions for the regulated *nmt1* promoter.

phenotype characteristic of cell cycle mutants, and show abnormal morphologies of branched and bent cells. In contrast, *wee1-50 cdc25-22 win1-1* cells transformed with *pwis2-3* undergo continued division, albeit at a cell size slightly greater (~1.5-fold) than that of wild-type cells, and are of normal shape.

Previous subcloning and transposon mutagenesis analysis predicted that the *wis2<sup>+</sup>* gene would lie within *plwis2-1*, a subclone containing a 5 kb fragment of *pwis2-3*, to the right of the *BglII* restriction site indicated in Figure 1 (Warbrick and Fantes, 1992). The subclone *pSC2-2* was found to be non-functional (Warbrick and Fantes, 1992), suggesting that sequences which lie to the right of the *HindIII* site indicated in Figure 1 are important for *wis2<sup>+</sup>* suppression activity. The DNA sequence was determined for a 1960 nt region extending from 135 nt to the left of *HincII* (1) indicated in Figure 1, to 80 nt to the right of the *PstI* site indicated. This nucleotide sequence contained an uninterrupted open reading frame (ORF) of 1068 nucleotides (Figure 2). Consistent with the predicted ORF of 1068 nt, a transcript of ~1500 nt was detected by Northern hybridization (see Figure 8). This transcript was shown to be present at a constant level throughout the cell cycle (P.Kersey, personal communication).

To confirm that this ORF was indeed responsible for *wis2<sup>+</sup>* activity, a multicopy plasmid, containing the 1.6 kb *HincII* fragment ligated into the vector *pIRT2* (*plwis2-2*), was introduced into *wee1-50 cdc25-22 win1-1* and shown to suppress its conditional lethal phenotype. As no other ORFs longer than 200 nt are present in either orientation within the *HincII* fragment, it is most likely that the 1068 nt ORF is responsible for the suppression activity. To test this, the predicted *wis2<sup>+</sup>* ORF was placed under the control of the *S.pombe* regulatable *nmt1* promoter, and its ability to suppress *wee1-50 cdc25-22 win1-1* was examined. The cloning of the *wis2<sup>+</sup>* ORF involved the introduction of an *NdeI* restriction site at the putative initiation codon of *wis2<sup>+</sup>*, and the resulting *NdeI-HincII* fragment was cloned downstream of the *nmt1* promoter of *pREP1* (Maundrell, 1990). The resulting plasmid, *pRwis2*, was able to suppress the triple mutant phenotype in the absence of thiamine (de-repressing conditions for the *nmt1* promoter) but not in the presence of thiamine



Sp-wis2	.....MSTY	AYFKISIDGK	IQPTIYFELF	24		
Sp-cyp1	.....MSN	CFDFVIANGQ	PLGRIVFKLF	23		
Tg-CyP-20	KHPTRLRPGS	LPCVAFCLYS	SRLSTMPNPR	VFFDISIDKK	PAGRIEFELF	
Hu-CyP-18	.....VNPT	VFFDIAVDGE	PLGRVSEFELF	25		
Hu-CyP-40	.....MSHPSPO	AKPSNPSNPR	VFFDVIDIGE	RUGRIVLELF	37	
consensus	.....npr	vffdisidg	plgrivfeLF			
Sp-wis2	DNVVPKTKN	FASLNCNGPEK	D.....GRCL	TYKGSRFHRV	IKNFMLQGGD	69
Sp-cyp1	DDVVPKTAAN	FRALCTG.EK	GYG.....	YAGSTFHRV	IQPFMLQGGD	64
Tg-CyP-20	ADVVPKTAEN	FRALCTG.EK	GTGR.SGPKL	YKGCPEFHR	IQPFMLQGGD	
Hu-CyP-18	ADKVPKTAEN	FRALSTG.EK	GFG.....	YKGSCEFHR	IQPFMLQGGD	66
Hu-CyP-40	ADVVPKTAEN	FRALCTG.EK	GIGHTHTGKPL	HFKGCPEFHR	IKKFMIQGGD	87
consensus	advvpktaen	FraLctG.EK	g.g...g.l	.ykGspFHR	IqpfM.QGGD	
Sp-wis2	FTRNGTGGG	SIYGEKFEDE	NFELKHKDPF	LLSMANAGPN	TNGSQFFITT	119
Sp-cyp1	FTRNGTGGK	SIYGEKFPDE	NFALKHKNPK	LLSMANAGPN	TNGSQFFITT	114
Tg-CyP-20	FTRNGTGGG	SIYGEKFADE	NFSYKHSEPF	LLSMANAGPN	TNGSQFFITT	
Hu-CyP-18	FTRHNGTGGK	SIYGEKFEDE	NFLLKHTGPK	LLSMANAGPN	TNGSQFFITT	116
Hu-CyP-40	FSNQNGTGGG	SIYGEKFEDE	NFHYKHDRGK	LLSMANAGPN	TNGSQFFITT	137
consensus	FtrngTGGG	SIYGEKFeDE	NF.LKHKdpG	LLSMANAGPN	TNGSQFFITT	
Sp-wis2	VPTPMLDGKH	VVFGKVIQGG	STVRTIENLE	TKNDPVPVVP	VIEECGCTK	169
Sp-cyp1	VVTPMLDGKH	VVFGVEVTEGM	DVVKVVEVSLG	SNSGATRARI	VIDKCGTV..	162
Tg-CyP-20	VPCPMLDGKH	VVFGKVVAGQ	EVVKMMEAEQ	RSNGQPKCAV	EISSCGQLS*	
Hu-CyP-18	AKTEWLDGKH	VVFGKVKEGM	NIVEAMERFG	SRNGKTSKKI	TIADCGQLE.	165
Hu-CyP-40	VPTPMLDGKH	VVFGQVIKGI	GVARILENVE	VKGEKPAKLC	VIAECGLKE	187
consensus	vptpWLDGKH	VVFGKViEGm	.vv..mEnlg	skngkp.k..	vIaeCG.L..	

**Fig. 3.** Alignment of the CyP-18 domain of wis2 with cyclophilins. The Cyp-18 domain of wis2 is aligned with cyp1, the 18 kDa type cyclophilin of *S.pombe* (de Martin and Philipson, 1990), CyP-20 of *Toxoplasma gondii* (High *et al.*, 1994), human CyP-18 (Harding *et al.*, 1986) and human CyP-40 (Kieffer *et al.*, 1993). On the bottom line, upper case letters indicate identical (5/5) amino acids. Lower case letters indicate identity between at least three amino acids. An asterisk indicates the position of the conserved tryptophan residue of the CyP-18 domain, which is replaced by a His residue in wis2 and CyP-40. All sequences are numbered according to the amino acid position relative to the predicted initiating methionine, except for CyP-20 of *T.gondii*, of which the position of the initiating methionine is unknown (High *et al.*, 1994).

addition, a region consisting of a three unit TPR-like domain was identified in both FKBP-59 and human ERBC (Ratajczak *et al.*, 1993). TPR domains contain a 34 amino acid motif that are presumed to form jointed helical structures each with a 'knob' and 'hole', and it has been suggested that these structures play a role in protein-protein interactions (Hirano *et al.*, 1990; Sikorski *et al.*, 1990; Lamb *et al.*, 1994). TPR domains have been found in a diverse group of proteins functioning, for example, in mitosis, transcription, splicing, import and neurogenesis (reviewed in Goebel and Yanagida, 1991). Two out of the three TPR units identified in ERBC are conserved in wis2, while the third unit in wis2 only remotely resembles the first two. It should also be noted that the TPR units identified in ERBC are imperfect when compared with the consensus sequence of TPR units suggested by Hirano *et al.* (1990) and Sikorski *et al.* (1990). The repeats of wis2, ERBC or FKBP-59 are more similar to those identified in STI1, a stress-inducible protein from yeast, IEF, a heat shock- and transformation-sensitive human protein and MAS70, a yeast outer mitochondrial membrane protein (Ratajczak *et al.*, 1993).


**Deletion and overexpression of wis2<sup>+</sup> in wild-type and cell cycle mutant cells**

The wis2<sup>+</sup> gene was deleted from the chromosome by one-step gene replacement (Rothstein, 1983). The deletion was performed using the 1.8 kb *S.pombe ura4<sup>+</sup>* gene, which was used to replace all coding sequences of wis2<sup>+</sup> excluding 12 bp at the 3' end (see Figure 5). A linearized DNA fragment containing the disrupted wis2 gene was integrated into the chromosome of a diploid strain by homologous recombination. Six ura<sup>+</sup> diploid strains were subjected to Southern blot analysis, and preliminary analysis of EcoRI hybridization fragments suggested that

**A**

Hu-FKBP59	PYGLERAIQR	MEKGEHSIVY	LKPSYAFGSV	GKEKFIQIPP	AELKYLHLK	250
Hu-CyP40	ECG.....E	LKEGDDGGIF	PK.....DGS	GDSHPDFPD	A...DIDLK	214
wis2	.....TKDQIEAP	KP.....DVT	GDSLSEFPDD	Y.....EGD.K	195	
consensus	.....gd.s.i.	.k.....dgs	Gds...f.p.d	a...evdIK		
Hu-FKBP59	SFEKAKESWE	MNSEEKLEQS	TIVKERGTIVY	FKEGKYQAL	LQYKIVSWL	300
Hu-CyP40	DVDKI.....	LLIT	EDLKNIGNTF	FKSQNWMAI	KKYAEVLRV	253
wis2	SETAI.....	FKIA	SDLKGIANKQ	FAQQNLDTAV	AKWQKALRYL	234
consensus	s...ki.....	l.is	edLk.ign..	Fk.qn...A.	.kykk.lryl	
Hu-FKBP59	EYESSFSNEE	AQKA.....	QALRLASHL	NLAMCHLKLQ	AFSAAIESCN	343
Hu-CyP40	D.SSKAVIET	ADRA.....K	LQPTALSCVL	NIGACKLRMS	NWQGAIDSC	297
wis2	M.EYVPVND	SKESPWFKE	YNALRSYIA	NLALVALKQN	KPQEAIRNAN	283
consensus	e.ess.sne.	a.ka.....	qalrls.l	Nla.c.LK..	a.q.Ai.scn	
Hu-FKBP59	KALELDSNNE	...KGLFRR	GEAHLAVNDF	ELARADFQKV	LQLYPNKAA	389
Hu-CyP40	EALDELPSNT	...KALYLR	AQQWQGLKEY	DQALADLKA	QGIAPEDKAI	343
wis2	IVIEASNTE	LEKQKAYYR	GCAQGLLNK	EES...EKA	LAKAGNDPAI	329
consensus	.aIEld.sne	...KalyRr	g.a...lk.f	d.a.ad..Ka	lq.ap.dkai	
Hu-FKBP59	KTQLAVCQR	IRRQLAREKK	LYANMRERLA	EENKAKAEA	SSGDHPTDTE	416
Hu-CyP40	QAELLKVKQ	IKAQKDEKA	YVAKMRA*	.....	.....	370
wis2	SKKLAERIQ	KKDYKRRQK	AYAKMRRQ	.....	.....	356
consensus	.a.La...Qk	ikaqk.rekk	.YAKM	.....	.....	


**B**



**Fig. 4.** Comparison between wis2, CyP-40 and FKBP-59. (A) The C-terminal region of wis2 is aligned with human CyP-40 and human FKBP-59. The consensus sequence derived from comparisons of the above protein sequences and that of rabbit FKBP-59 and bovine CyP-40 is shown at the bottom line. A putative calmodulin binding site is boxed (Lebeau *et al.*, 1992). (B) Schematic representation of wis2, CyP-40 and FKBP-59 proteins.

in all diploids strains the same single integration event had occurred (data not shown). One of these ura<sup>+</sup> diploid strains was analysed further by Southern blotting, and *PstI* bands with the expected sizes of 3.75, 2.2 and 2.1 kb were obtained (Figure 5A). Tetrad analysis showed that all four haploid spores of the heterozygous diploid produced colonies at 28°C, indicating that the wis2<sup>+</sup> gene is non-essential for viability under normal growth conditions. Southern hybridization of restriction-digested DNA from the haploid spore clones with radiolabelled *PstI* fragment of wis2<sup>+</sup> showed the expected pattern of hybridizing bands (2.2 and 2.1 kb for ura<sup>+</sup> cells and 3.75 kb for ura<sup>-</sup> cells). The lack of any hybridization signal in ura<sup>+</sup> haploid cells when probed with the *BglIII-HindIII* fragment of wis2<sup>+</sup>, which contains those sequences removed in the DNA construct used for wis2 disruption, confirmed that ura<sup>+</sup> haploid cells represent a deletion of the wis2<sup>+</sup> gene (Figure 5B).


Microscopic examination failed to detect any difference in cell size or morphology between wis2<sup>+</sup>-deleted cells (*wis2Δ*) and wild-type cells, over a range of temperatures from 20 to 36°C. Possible interactions of wis2Δ with cell



**Fig. 5.** Deletion of *wis2* gene. Upper panel. Schematic representation of deletion by the one-step gene replacement method (Rothstein, 1983). The *S.pombe ura4<sup>+</sup>* gene was used to replace the *BglII-HincII* fragment of *wis2<sup>+</sup>* (for details see Materials and methods). Lower panels. Southern blot analysis of *wis2*-deleted strains. *S.pombe* genomic DNA prepared from a disruptant diploid (D), its haploid *ura<sup>+</sup>* (*U<sup>-</sup>*; *wis2* $\Delta$ ) and *ura<sup>-</sup>* (*U<sup>-</sup>*) progeny cells, and haploid wild-type cells (W). Genomic DNA samples were digested with *PstI*, separated by agarose gel electrophoresis and Southern blotted. (A) Probed with a *PstI* fragment from plwis2-1. (B) Probed with a *BglII-HindIII* fragment from plwis2-1.

cycle mutations were investigated by crossing a *wis2* $\Delta$  strain with strains carrying the following mutations: *win1-1*, *cdc25-22*, *wee1-50*, *cdc2-33* and *cdc13-117*. No defects associated with the deletion of *wis2<sup>+</sup>* were noticed in any case. Also, no interactions were observed with a deletion of the *wis1<sup>+</sup>* gene, a MAPKK homologue isolated in the same screen as *wis2<sup>+</sup>* (Warbrick and Fantes, 1991). We have also investigated whether the *wis2* deletion allele has any effect in the double mutant *wee1-50 cdc25-22* and the triple mutant *wee1-50 cdc25-22 win1-1*. However, no effects on cell length at division or any other effects were observed (data not shown). The lack of effect of deletion of *wis2* in *wee1-50 cdc25-22 win1-1*, a genetic background in which overexpression of *wis2<sup>+</sup>* shows a strong suppression phenotype, could be explained by the presence of another gene which acts redundantly with *wis2<sup>+</sup>*.

The effect of overexpression of *wis2<sup>+</sup>* was examined in wild-type cells and in a variety of cell cycle mutants, as genetic interactions might give a clue to the mechanism by which *wis2<sup>+</sup>* suppresses the cell cycle defect of *wee1-50 cdc25-22 win1-1*. pRwis2 (strongly overexpressing *wis2<sup>+</sup>* from the *nmt1* promoter, see above) was used to transform various strains. These include wild-type and the cell cycle mutants described above. Wild-type cells transformed with pRwis2 in the absence of thiamine showed an ~40-fold increase in *wis2<sup>+</sup>* mRNA level compared with the wild-type level (assessed by Phosphor-Imager analysis of Northern blots, data not shown). No phenotypic effect associated with the introduction of pRwis2 was observed in the above genetic backgrounds, except in the background of the triple mutant *wee1-50*



**Fig. 6.** Detection of the proteins *wis2*, *cyp1* and *cyp1-wis2*. Total protein extracts were prepared of the following strains: *wis2* $\Delta$  (lane 1), wild-type 972 *h<sup>-</sup>* (lane 2), and *cdc25-22 wee1-50 win1-1 leu1-32 h<sup>-</sup>* transformed with pRwis2 (lane 3), plwis2-1 (lane 4), plcyp1-wis2 (lane 5) or plcyp1 (lane 6). Cells containing the pRwis2 plasmid were grown under derepression conditions for full activity of the *nmt1* promoter in pRwis2. Each lane contains ~40  $\mu$ g of total protein. Protein extracts were separated on SDS-PAGE gels and blotted under denaturing conditions. The enhanced chemiluminescence (ECL) detection system was employed using polyclonal antibodies raised against human CyP-A. Autoradiography films were exposed for 5–10 s.

*cdc25-22 win1-1*, where pRwis2 suppressed the elongated and lethal phenotype of the strain, as expected.

Finally, possible effects of *wis2<sup>+</sup>* deletion or overexpression in the presence of CsA were investigated. We observed that the presence of CsA in the growth medium (50–400  $\mu$ g/ml) resulted in an increased proportion of septated cells, as well as the presence of multiseptated cells, similar to the effect reported by Yoshida *et al.* (1994). As members of the cyclophilin family are known to mediate the effects of CsA in mammalian and *S.cerevisiae* cells, the effects of CsA on a *wis2* $\Delta$  strain and on cells overexpressing *wis2<sup>+</sup>* were examined. Neither deletion of *wis2<sup>+</sup>* nor overexpression affected the phenotype of *S.pombe* cells treated with CsA, suggesting that *wis2<sup>+</sup>* does not participate in mediating its effect.

#### Detection of *wis2* protein

Detection of the *wis2* protein was performed by immunoblotting with polyclonal antibodies raised against human Cyp-A protein (an 18 kDa cytosolic cyclophilin; a kind gift from F.Etzkorn and C.Walsh). Total *S.pombe* protein extracts were separated on SDS-PAGE gels, blotted and antibody binding proteins were detected by using the ECL immunodetection system (Figure 6). Cells transformed with plwis2-1 exhibited increased expression of an ~40 kDa protein (lane 4) compared with wild-type (lane 2), or cells transformed with the control plasmid pIRT2 (data not shown). The increased level of a 40 kDa protein species is consistent with the predicted molecular weight of *wis2*, and indicates that the human CyP-A antibodies cross-react with the overexpressed *S.pombe wis2* cyclophilin-like protein.

In cells carrying pRwis2, a further increase in the level of the 40 kDa protein was observed under derepressing conditions for the *nmt1* promoter (lane 3). The appearance of ~18 and ~30 kDa protein bands was also observed in cells transformed with pRwis2, and may indicate a proteolytic degradation of the overexpressed *wis2* protein. The presence of an elevated level of the 18 kDa species may reflect the presence of a particularly sensitive proteolytic site between the cyclophilin and the C-terminal domains of *wis2*.

Reaction of the antibodies with protein extracts of wild-type and *wis2Δ* cells (lanes 1 and 2) was poor and, therefore, difficult to interpret. However, a signal with an 18 kDa protein species probably indicates a cross-reaction with *S.pombe* proteins of the 18 kDa cyclophilin subgroup. In a longer exposure of the blot shown in Figure 5A (data not shown), protein extracts of a *wis2Δ* strain showed the same pattern of bands as observed in wild-type cells, including the 40 kDa species. This may indicate the presence of another 40 kDa cyclophilin-like protein, in addition to *wis2*.


**The C-terminal domain of *wis2*<sup>+</sup> is essential for its suppression activity and appears to confer specificity on the cyclophilin domain**

The unusual structure of *wis2* prompted us to carry out a structure–function analysis, using the suppression of the conditional lethal phenotype of a *wee1-50 cdc25-22 win1-1* strain to test for *in vivo* function. This suppression activity is referred to hereafter as *wis2* activity. Previous subcloning analysis (Warbrick and Fantes, 1992) suggested that the C-terminal domain is required for *wis2* activity: the subclone pSC2-2 lacks most of the C-terminal region (129 amino acids) and is unable to confer *wis2* activity (see Figure 1).

The requirement for the C-terminal domain of *wis2* for activity was investigated further by examining the ability of the 18 kDa *S.pombe* cyclophilin-like protein, *cyp1* (de Martin and Philipson, 1990) to confer *wis2* activity. The *EcoRI* fragment of a genomic clone of *cyp1*<sup>+</sup> was cloned into the *S.pombe* plasmid pIRT2. This *EcoRI* fragment contains 500 bp upstream of the predicted initiating ATG codon, the entire predicted *cyp1*<sup>+</sup> ORF and 270 bp of the downstream sequences. The resultant plasmid, p*cyp1*, was transformed into the triple mutant strain. The *cyp1*<sup>+</sup> clone was unable to suppress the conditional lethal phenotype: no colony formation occurred at the restrictive temperature on minimal medium, and cells displayed the typical lethal phenotype of highly elongated, bent and branched cells (Figure 7). An increased level of an ~18 kDa protein species was identified with the anti-human Cyp-A antibodies in protein extracts of cells transformed with p*cyp1*, confirming overexpression of the *cyp1*<sup>+</sup> gene product (see Figure 6, lane 6).

The observation that *cyp1*<sup>+</sup> could not confer *wis2* activity when overexpressed may be explained in at least two ways: the *wis2* cyclophilin domain is itself necessary, but not sufficient, for *wis2* activity, or an intrinsic substrate specificity is contained within the cyclophilin domain. In order to test these possibilities, the C-terminal region of *wis2* was fused in-frame to the N-terminal Cyp-18 domain of *cyp1*, and the ability of the hybrid protein to confer *wis2* activity was examined.

The hybrid *cyp1-wis2* gene contains the predicted ORF of *cyp1*<sup>+</sup> (excluding the last codon, encoding valine) followed by *wis2*<sup>+</sup> sequences encoding the C-terminal 188 amino acids (see Materials and methods for details). *cyp1-wis2* was cloned into pIRT2, and the resulting plasmid p*cyp1-wis2* was transformed into the *cdc25-22 wee1-50 win1-1* strain. Western blot analysis indicated that the transformants overexpressed a 40 kDa protein, consistent with the predicted molecular weight of the hybrid protein (Figure 6, lane 5). p*cyp1-wis2* was able




**Fig. 7.** Suppression activity of *cyp1*<sup>+</sup> and *cyp1-wis2*. (A) Schematic diagram representing the *cyp1*<sup>+</sup> and *cyp1-wis2* genes: a striped box represents the Cyp-18 domain of *wis2*, filled boxes represent the C-terminal region of *wis2* and open boxes represent *cyp1*. (B) *cdc25-22 wee1-50 win1-1 leu1-32 h<sup>-</sup>* transformed with either pIRT2, p*wis2-2*, p*cyp1* or p*cyp1-wis2* were grown on minimal plates at the permissive temperature, then streaked onto fresh minimal plates and incubated at the restrictive temperature (35°C) for 6 days.

to suppress the triple mutant phenotype with comparable efficiency to that of functional subclones of *wis2*<sup>+</sup> in pIRT2 plasmids (Figure 7), consistent with the suggestion that the C-terminal domain of *wis2* confers specificity onto the *cyp1* Cyp-18-like *S.pombe* protein.

***wis2*<sup>+</sup> transcript is heat shock induced**

The implication of cyclophilins and, in particular, the finding that FKBP-59 is identical to the previously identified heat-shock protein hsp56 (Yem *et al.*, 1992) led us to search for heat-shock elements (HSEs) in the promoter region of *wis2*<sup>+</sup>. HSEs serve as a binding site for the heat shock transcriptional activation factor HSF and consist of inverted repeats of the sequence *nGAAn* which is conserved from yeast to mammals (Perisic *et al.* 1989). Indeed, a putative HSE of the sequence CTAGAAGTTT-CGTAG is present 218 bp upstream of the putative initiating ATG codon (Figure 2). Consequently, we examined the level of *wis2*<sup>+</sup> RNA after heat-shock treatment. A 10- to 15-fold increase of *wis2*<sup>+</sup> mRNA level was observed after a shift of exponentially growing wild-type cells from 25 to 37°C for 30 min. A further 2-fold increase was observed when cells were shifted from 25 to 42°C. A time course experiment in which wild-type cells were shifted from 25 to 42°C showed that *wis2*<sup>+</sup> RNA level increased during the first 30 min, and then began to decline (Figure 8). Although the increased level of *wis2*<sup>+</sup> RNA upon heat shock suggests a role for *wis2*<sup>+</sup> in the heat-shock response, preliminary experiments failed to show a significant difference in the ability of cells deleted for *wis2*<sup>+</sup> to survive heat shock, compared with wild-type cells. This preliminary analysis included time course experiments examining the ability of cells growing at 25°C to survive heat shock at 42 or 49°C during a 45 min period (data not shown).



**Fig. 8.** Increased level of *wis2* transcript upon heat shock. Wild-type cells were grown at 25°C in yeast extract medium and shifted to 37 or 42°C. Samples were taken at the times indicated for preparation of RNA. RNA samples were separated on an agarose formaldehyde gel, Northern blotted and probed sequentially with the *Bgl*III–*Hinc*II fragment of *plwis2-1* and the *Eco*RI fragment internal to the *S.pombe* *adh*<sup>+</sup> gene as loading control. Relative amounts of RNA were determined by PhosphorImager analysis.

## Discussion

### Characteristics of the structure and function of *wis2*

The *wis2*<sup>+</sup> DNA sequence predicts a 40.1 kDa cyclophilin-like gene product. The N-terminus of the gene encodes the 18 kDa domain of cyclophilins and is followed by a C-terminus of 188 amino acids. *wis2*<sup>+</sup> is structurally homologous to bovine and human CyP-40 (isolated as CsA binding proteins; Kieffer *et al.*, 1993) and to human ERBC (isolated as a component of the inactive oestrogen receptor complex; Ratajczak *et al.*, 1993), indicating that the 40 kDa subgroup of cyclophilins is conserved throughout evolution.

*Wis2* and CyP-40/ERBC share two distinct features. First, both contain a similar C-terminal region (31% identical), containing a putative calmodulin binding motif and amino acid sequences which resemble TPR domains. Secondly, in both proteins, the highly conserved tryptophan residue of the CyP-18 domain (Trp121 in human CyP-18) is substituted by histidine. Trp121 was suggested, based on mutagenesis analysis, to be important for the interaction with CsA *in vitro* but to have little effect on PPIase activity (Liu *et al.*, 1991b). Also, although human CyP-40 was isolated as a CsA binding protein, its elution from CsA affinity columns prior to CyP-18 suggested a lower affinity for CsA compared with CyP-18 (Kieffer *et al.*, 1992). The importance of the tryptophan residue for high affinity for CsA may partially explain our *in vivo* observation that neither overexpression nor deletion of *wis2*<sup>+</sup> affected the multiseptated phenotype of *S.pombe* cells treated with CsA. Other factors, like subcellular localization or protein–protein interactions, are also likely to determine which members of the cyclophilin family participate in mediating the *in vivo* effects of CsA (see Koser *et al.*, 1991; McLaughlin *et al.*, 1992).

The substitution of tryptophan by histidine both in *wis2* and mammalian CyP-40 is striking when compared with the high conservation of Trp121 in other eukaryotic cyclophilins. However, the significance of this substitution for biological activity, if any, is not clear. In particular, the structure–function analysis of *wis2*, reported here,

indicates that replacement of the CyP-18 domain of *wis2* with the 18 kDa *S.pombe* cyclophilin *cyp1*, which contains the conserved tryptophan residue, resulted in a functional hybrid protein with respect to the suppression activity of *wee1-50 cdc25-22 win1-1*. Therefore, the presence or absence of the conserved tryptophan does not appear to affect the *in vivo* function of the suppression activity of *wis2*.

The C-terminal region of *wis2* and CyP-40/ERBC shows structural similarities with FKBP-59, which contains a structurally unrelated PPIase domain. Interestingly, both FKBP-59 and CyP-40/ERBC have been identified in the inactive form of steroid receptors, which also contain hsp90 and hsp70 (Tai *et al.*, 1986, 1992; Ratajczak *et al.*, 1993). It has been suggested that the immunophilins, together with the heat-shock proteins, form hetero-complexes which may facilitate the assembly/disassembly or intracellular transport of steroid receptors (Tai *et al.*, 1992; Pratt, 1993; Ratajczak *et al.*, 1993). The C-terminal non-PPIase domain of either FKBP59 or CyP-40/ERBC is required for association with hsp90 (Pratt, 1993; Radanyi *et al.*, 1994; Hoffmann and Handschumacher, 1995), and mutational analysis indicates that the TPR motifs localized in the C-terminal domain of FKBP-59 have a role for hsp90 binding (Radanyi *et al.*, 1994). The TPR motifs in the C-terminal domain of CyP-40/ERBC are likely to have a similar role. The finding that the *S.cerevisiae* hsp90 homologue, hsp82, associates with a 45 kDa cyclophilin-like protein is the first indication that macromolecular complexes containing hsp90 and immunophilins may be conserved from yeast to human (Chang and Lindquist, 1994). The full sequence of the novel *S.cerevisiae* cyclophilin-like protein is not known yet, but N-terminal amino acid sequence analysis of the 45 kDa protein showed clear homology to cyclophilins; in particular, high homology was found to the human CyP-40 amino acid sequence (Chang and Lindquist, 1994).

Apart from *wis2*<sup>+</sup>, only one other cyclophilin-like gene has been reported in *S.pombe*. *cyp1*<sup>+</sup> was isolated in a screen of a *S.pombe* genomic library, employing degenerate oligonucleotides containing conserved sequences of cyclophilins (de Martin and Philipson, 1990). We have demonstrated here that *cyp1*<sup>+</sup> is not capable of suppression of the *wee1-50 cdc25-22 win1-1* lethal phenotype. In contrast, a hybrid protein that contains the *cyp1* amino acid sequence fused to the C-terminal region of *wis2* is an efficient suppressor of *wee1-50 cdc25-22 win1-1*. The C-terminal domain of *wis2* is thus able to confer activity on the cytosolic form of the *S.pombe* cyclophilin. These results are consistent with the suggestion that the 18 kDa cyclophilins are involved in housekeeping activities, but become specialized when found as a domain within a complex protein (Stamnes *et al.*, 1992). The C-terminal region of *wis2* may confer specificity on the molecule either by targeting the molecule to a specific location or, more likely, by determining protein–protein interactions between *wis2* and partner proteins. An intriguing possibility is that the C-terminal region of *wis2* and the *S.pombe* hsp90 homologue interact physically, similar to the interactions found between hsp90 and human CyP-40 (Hoffmann and Handschumacher, 1995) or the 45 kDa cyclophilin protein of *S.cerevisiae* (Chang and Lindquist,



1994). Such a hsp90–Cyp-40 interaction may play a role in the suppression activity of *wis2* (see also below).

One possibility yet to be examined directly is that the C-terminal domain of *wis2* alone is capable of suppressing the lethal phenotype of *wee1-50 cdc25-22 win1-1*. Although this possibility has not been tested experimentally, the high conservation of the Cyp-18 domain throughout evolution, and the functional role suggested for the Cyp-18 domain in other proteins, strongly suggest that this domain plays a role in the activity of *wis2*. In a preliminary analysis, we aimed to address the question of the role of the Cyp-18 domain of *wis2* in the suppression activity by introducing a short deletion (Ser102–Gly112) or any of two point mutations (replacement of His129 by proline or leucine) into the Cyp-18 domain of *wis2*. These mutations are localized to highly conserved amino acids, which have also been mapped, based on the solution for the three-dimensional structure of human Cyp-18 (Kallen *et al.*, 1991; Thériault *et al.*, 1993), close to or at the PPIase active site. The resultant mutated genes were no longer able to confer *wis2* activity when expressed from a multicopy yeast plasmid (overexpression of *wis2* mRNA was confirmed by Northern blot analysis; data not shown). However, Western blot analysis suggested that the mutated proteins were not expressed in *S.pombe* cells to the same level as the wild-type *wis2* protein (data not shown). At the moment, it is not clear whether the inability to confer *wis2* activity stems from a specific defect within the cyclophilin active site, whether it is a consequence of the instability of the mutated proteins *in vivo* or due to the inability of the anti-human Cyp-18 antibodies to recognize the mutated *wis2* proteins.

#### Implication of *wis2*<sup>+</sup> in heat-shock response and cell cycle

The isolation of *wis2*<sup>+</sup> as a multicopy suppressor of the cell cycle defect of a *wee1-50 cdc25-22 win1-1* strain suggests it has a role in the regulation of mitosis. When overexpressed, the effect of *wis2*<sup>+</sup> is only apparent in the absence of the major control elements *wee1* and *cdc25*. Overexpression of *wis2*<sup>+</sup> has no apparent effect on single mutants defective for any of the major regulators of mitosis, *cdc2*, *cdc13* or *wee1*. The importance of the *wee1* and *cdc25* defects in the suppression activity of *wis2*<sup>+</sup> is also indicated by its ability to suppress the defects of other strains carrying *wee1-50* and *cdc25-22*, specifically, in combination with *mcs3*, *mcs4* or *mcs6* mutations (Warbrick and Fantes, 1992). The *mcs* mutations were isolated as suppressors of mitotic catastrophe phenotype in *wee1-50 cdc2-3w* cells (Molz *et al.*, 1989), and this incidentally lends support to the involvement of *wis2*<sup>+</sup> in regulation of the G<sub>2</sub>–mitosis transition.

In cells lacking both *cdc25* and *wee1*, the phosphorylation level of *cdc2* Tyr15 appears to be determined by other 'backup' elements such as *mik1* and *pyp3* (Lundgren *et al.*, 1991; Millar *et al.*, 1992), and regulation under these conditions may be much less stringent than normal. Indeed, *wee1 cdc25* double mutant cells are very heterogeneous in size, suggesting that the control is quite finely balanced. One explanation for the action of *wis2* is that it interacts with an element such as *mik1* or *pyp3*, but that this interaction only becomes apparent when *mik1* and *pyp3* become major regulators of entry into mitosis.

Table I. Strains used in this study

ED812	972 <i>h</i> <sup>-</sup>
ED566 <sup>a</sup>	<i>win1-1 wee1-50 cdc25-22 leu1-32 h</i> <sup>-</sup>
ED623 <sup>a</sup>	<i>win1-1 leu1-32 h</i> <sup>+</sup>
ED628	<i>cdc2-33 leu1-32 ura4-D18 h</i> <sup>-</sup>
ED678	<i>win1-1 leu1-32 ura4-D18 ade6-M216 h</i> <sup>-</sup>
ED918	<i>cdc13-117 ura4-294 leu1-32 h</i> <sup>-</sup>
ED866	<i>cdc25-22 leu1-32 ura4-D18 h</i> <sup>-</sup>
ED909	<i>wee1-50 leu1-32 ura4-D18 h</i> <sup>-</sup>
ED947 <sup>b</sup>	<i>wis1::his1<sup>+</sup> his1-102 ade6-M216 ura4-D18 h</i> <sup>+</sup>

<sup>a</sup>Ogden and Fantes, 1986.

<sup>b</sup>S.Stettler, personal communication.

An alternative explanation is that *wis2* interacts with an essential component of the mitotic regulatory machinery such as *cdc2* or *cdc13* but that, again, this is only important in cells when the regulation is rather labile.

Deletion of the gene has not revealed any effects so far, even in genetic backgrounds where we would most expect it: no phenotypic effects were observed when the *wis2*-deleted allele was combined with the combination of *wee1-50*, *cdc25-22* and *win1-1* alleles. The most likely explanation is that another gene exists in *S.pombe* which acts redundantly with *wis2*<sup>+</sup>. This explanation is plausible, particularly in view of the high redundancy already suggested for the family of cyclophilins (for example, see McLaughlin *et al.*, 1992).

Whatever its molecular targets, the likely function of *wis2* as a molecular chaperone suggests possible ways in which it might interact with the mitotic control machinery: for instance, it might serve to stabilize particular regulatory proteins, or mediate their transport between the cytoplasm and the nucleus. As *wis2* presumably acts to mediate positively progression through the G<sub>2</sub>–mitosis transition, we have examined the level of proteins of two major positive regulators of the G<sub>2</sub>–mitosis transition. We have been unable to detect any difference in the levels of *cdc13* or *cdc25* proteins in a *wis2Δ* strain compared with the level of these proteins in wild-type cells (J.C., unpublished observations). However, other investigations suggest that the heat-shock response and cell cycle control are connected: heat shock specifically delays mitosis in *S.pombe* and other cells (Polanshek, 1977), and a mutation in the HSF of *S.cerevisiae* shows a cell cycle arrest phenotype consistent with a G<sub>2</sub> delay (Smith and Yaffe, 1991). A recent intriguing observation is that a mutation in the *S.pombe* hsp90 homologue, *swol-26*, suppresses the lethal phenotype of overproduction of *wee1*, perhaps by direct interaction between the proteins (Aligue *et al.*, 1994). It is possible, particularly in view of the emerging evidence of conserved physical association of cyclophilin-40 and hsp90, that *wis2* exerts its effect on mitosis by modulating the activity of an hsp90 homologue.

## Materials and methods

### Yeast strains and media

Details of the strains used in this study are given in Table I. Media for the propagation of *S.pombe* were as described by Moreno *et al.* (1991). The standard genetic procedures of Gutz *et al.* (1974) were followed. All strains were derived from the two wild-type strains 972 *h*<sup>-</sup> and 975 *h*<sup>+</sup>. CsA was a gift of Sandoz Pharma, Basle, Switzerland. For stock solution, 1 mg of CsA was dissolved in 1 ml of absolute ethanol/0.1% Tween 20; filter sterilized and kept in a glass container at



4°C. CsA was added to a final concentration of 50–400 µg/ml in liquid or agar containing media.

### Plasmids

A subclone of *wis2*<sup>-</sup> in the Pharmacia vector pTZ18R (pSC3-16; Warbrick and Fantex, 1992) was used as the parental plasmid for *wis2* subclones. This plasmid is referred to here as pTZ*wis2*-1. The genomic insert of pTZ*wis2*-1 was released by double restriction digest with *Sma*I and *Sall*I, and was cloned between the *Sma*I and *Sall*I polylinker sites of the yeast multicopy vector pIRT2 (Booher and Beach, 1986). The resultant plasmid was named p*wis2*-1. Subsequently, the 1.6 kb *Hinc*II fragment of p*wis2*-1 was cloned into the *Sma*I site of the vector pIRT2 to give p*wis2*-2. For stronger overexpression of *wis2*<sup>-</sup>, the gene was cloned into the pREP1 plasmid under the control of the *nmt1* promoter (Maundrell, 1990). For this cloning, an *Nde*I restriction site was introduced into pTZ*wis2*-1 at the putative initiation codon of *wis2*<sup>+</sup> by oligonucleotide-directed *in vitro* mutagenesis (Mutagene Phagemid Kit, Bio-Rad), using the oligonucleotide 5'-CATTGTTTTTTTTGCACCAT-ATGACTTAC-3'. The resulting *Nde*I-*Hinc*II fragment of the mutated pTZ*wis2*-1 plasmid was cloned downstream of the *nmt1* promoter of pREP1, to give p*Rwis2*.

An *Xba*I genomic fragment of *cyp1*<sup>+</sup> cloned into the pBS<sup>+</sup> plasmid (Stratagene) was a kind gift of R.de Martin (pBS*cyp1*; de Martin and Philipson, 1990; the name of the gene was agreed upon personal communication). The *cyp1*<sup>+</sup> gene was released from this plasmid by *Eco*RI digestion, the cohesive ends were filled-in, and the fragment was ligated with pIRT2 plasmid digested with *Sma*I. The resultant plasmid from this ligation was named p*cyp1*.

### DNA sequence analysis

The sequence of *wis2*<sup>-</sup> was determined by a combination of the phagemid system devised by Vieira and Messing (1987) and the chain termination sequencing method of Sanger *et al.* (1977). Nested deletions were prepared from pTZ*wis2*-1, using the Pharmacia Nested Deletion Kit. Dideoxy sequencing reactions using T7 DNA polymerase were performed with the Pharmacia T7 Sequencing Kit. The sequence of 1965 bp was determined on both strands. Analysis and homology searches were performed using the University of Wisconsin GCG package. The DNA sequence reported here has been deposited with the EMBL sequence database under the accession number X91981.

Sequence analysis was also performed to confirm all of the mutations introduced either into the *wis2*<sup>-</sup> or *cyp1*<sup>+</sup> genes.

### DNA and RNA manipulation

Yeast RNA was prepared as described by Kaufer *et al.* (1985) and DNA as described by Beach *et al.* (1982). Southern and Northern blot analysis was carried out using Gene Screen Plus (NEN) membranes following the preferred protocol suggested by the manufacturer. DNA probes were labelled with [<sup>32</sup>P]dCTP using the random oligonucleotide labelling procedure of Feinberg and Vogelstein (1983).

### Protein manipulations

Yeast total protein was prepared following the method described by Moreno *et al.* (1991). Protein concentration was estimated using the Pierce BCA Protein Assay kit. The Mini Trans blot cell (Bio-Rad) was used for blotting proteins from SDS-polyacrylamide gels by electric current. The membrane used for the blotting was 0.2 µm PVDF (polyvinylidene difluoride) membrane (Bio-Rad). Transfer was allowed to proceed for 1–1.5 h at 100–150 V. The Amersham ECL (enhanced chemiluminescence) system was used to detect the immobilized proteins. Using this system, *wis2*, *cyp1* and the *cyp1*-*wis2* fusion protein can be detected using polyclonal antibodies raised against human CyP-A, a kind gift of F.Etzkorn and C.Walsh, Harvard Medical School, Boston, MA.

### Polymerase chain reaction analysis of S.pombe cDNA library

A *S.pombe* cDNA library made in the yeast vector pREP3X was a gift from C.Norbury, IMM, ICRF, Oxford. The PCRs were performed using the GenAmp DNA reagent kit (Perkin Elmer Cetus). DNA template (0.1 µg) was used for the amplification reactions. Amplification was performed over 30 cycles as follows: 94°C for 2 min (denaturing), 55°C for 2 min (annealing), 72°C for 4 min (elongation). These cycles were completed by 72°C for 5 min, and then 25°C for 30 min.

### Construction of the wis2 deletion

A *Hind*III genomic fragment containing the *ura4*<sup>+</sup> gene was obtained from the plasmid pUC8/*ura4* (E.Warbrick, personal communication). The *ura4*<sup>+</sup> gene was released by *Hind*III digest and was cloned into

pBluescript KS<sup>+</sup> (Stratagene) at the *Hind*III restriction site, to give pBCura4. The *ura4*<sup>+</sup> gene was then released from pBCura4 by double restriction digest with *Bam*HI and *Hinc*II. The released fragment was ligated with pTZ*wis2*-1 double digested with *Bgl*III and *Stu*I restriction enzymes, resulting in the plasmid pTZ*wis2*::*ura4*. The replaced *wis2* sequence consists of 135 bp of 5'-non-coding sequences and 1056 bp of ORF sequences. The 4.2 kb *Kpn*I-*Sph*I fragment of pTZ*wis2*::*ura4* was used for yeast transformation by electroporation. This fragment contained the *ura4*<sup>+</sup> sequences flanked by ~1.8 and ~2.4 kb of sequences adjacent to *wis2*<sup>-</sup>. Approximately 2 µg of gel-purified *wis2* disrupted fragment were used to transform a diploid of the genotype *ade6*-*M210/ade6*-*M216 ura4*-*D18/ura4*-*D18 leu1*-32/*leu1*-32 *h*<sup>+</sup>/*h*<sup>-</sup>, and *ura*<sup>+</sup> transformants were selected.

### Construction of cyp1-wis2 hybrid

Construction of the *cyp1*-*wis2* hybrid was carried out to replace *wis2*<sup>+</sup> sequences encoding the CyP-18 domain with the *cyp1*<sup>+</sup> ORF. The *cyp1*<sup>+</sup> ORF contains two *Kpn*I restriction sites. The *Kpn*I site at position 208–214 in pBS*cyp1* (see Plasmids, above) was removed by oligonucleotide-directed *in vitro* mutagenesis (Mutagene Phagemid Kit, Bio-Rad), so that the *Kpn*I site at position 477–483 could be used for subsequent ligations. The removal of the *Kpn*I site using the oligonucleotide 5'-CTTCCACCGGTTCCGTTACCGCG-3' resulted in a silent mutation at the predicted Gly60 residue of the *cyp1* protein, and gave the plasmid pBS*cyp1*-K. In addition, a *Kpn*I site was introduced by oligonucleotide-directed *in vitro* mutagenesis into pTZ*wis2*-1 at the border between the cyclophilin and the C-terminal region of *wis2*<sup>+</sup> (see Figure 2). Introduction of this *Kpn*I site with the oligonucleotide 5'-GAAGAATGTGGTACCTGCACAAAGGATC-3' resulted in a silent mutation of the predicted Gly164 and Thr165 residues of *wis2*<sup>-</sup>. Subsequently, the *Kpn*I fragment of pBS*cyp1*-K, containing the *cyp1* ORF excluding the last 3 bp, was ligated with pTZ*wis2*-1-K digested with *Kpn*I, such that it replaced the CyP-18 domain of *wis2*<sup>-</sup>. The resultant plasmid was named pTZ*cyp1*-*wis2*. The hybrid gene *cyp1*-*wis2* was released from pTZ*cyp1*-*wis2* by *Sma*I and *Sall*I double restriction digest and was cloned between the *Sma*I and *Sall*I polylinker sites of the yeast multicopy vector pIRT2, to give p*cyp1*-*wis2*. Note that *cyp1*-*wis2* is predicted to be transcribed from the promoter of the *cyp1*<sup>+</sup> gene.

### Construction of wis2 mutated genes at the CyP-18 domain

Mutations at the CyP-18 domain of *wis2*<sup>+</sup> were introduced into pTZ*wis2*-1 by oligonucleotide-directed *in vitro* mutagenesis (Mutagene Phagemid Kit, Bio-Rad). The oligonucleotides used were: 5'-GGATGG-AAAGC(C/T)TGTTGTTTTGGC-3' for the introduction of the point mutations which replaced His129 with leucine or proline; and 5'-CATGATAAGCCTTCTGCTTTCTCAGTTCTTCATTACTAC-3' for the deletion of the 11 amino acids Ser102–Gly112. The mutated genes were released from the plasmid pTZ*wis2*-1 by double restriction digest with *Sma*I and *Sall*I and were cloned between the *Sma*I and *Sall*I polylinker sites of the yeast multicopy vector pIRT2.

### Acknowledgements

We would like to thank Emma Warbrick for the *wis2* clones, Dr R.de Martin for the *cyp1*<sup>+</sup> clone and Dr F.Etzkorn and Professor C.Walsh for the anti-human CyP-18 antibodies. We thank Paul Kersey for Northern blot analysis of the *wis2* transcript level in synchronous culture, and Stuart MacNeill for his thoughtful contribution to the content of this paper and for critical reading of the manuscript. We thank Malcolm Walkinshaw for helpful discussions, and for drawing our attention to aspects of cyclophilin structure. We also thank Joan Davidson and Aileen Greig for excellent technical support. R.W. was supported by a studentship from the Darwin Trust, Edinburgh.

### References

- Aligue,R., Akhavan-Niak,H. and Russell,P. (1994) *EMBO J.*, **13**, 6099–6106.
- Anderson,S.K., Gallinger,S., Roder,J., Frey,J., Young,H.A. and Ortaldo,J.R. (1993) *Proc. Natl Acad. Sci. USA*, **90**, 542–546.
- Baker,E.K., Colley,N.J. and Zuker,C.S. (1994) *EMBO J.*, **13**, 4886–4895.
- Beach,D., Durkacz,B. and Nurse,P. (1982) *Nature*, **300**, 706–709.
- Booher,R. and Beach,D. (1986) *Mol. Cell. Biol.*, **6**, 3523–3530.
- Callebaut,I., Renoir,J.-M., Lebeau,M.-C., Nassol,N., Burny,A., Baulieu,E.-E. and Mornon,J.-P. (1992) *Proc. Natl Acad. Sci. USA*, **89**, 6270–6274.

- Cardenas, M.E., Hemenway, C., Muir, R.S., Ye, R., Fiorentio, D. and Heitman, J. (1994) *EMBO J.*, **13**, 5944–5957.
- Chang, H.-C. J. and Lindquist, S. (1994) *J. Biol. Chem.*, **269**, 24983–24988.
- Clipstone, N.A. and Crabtree, G.R. (1992) *Nature*, **357**, 695–697.
- de Martin, R. and Philipson, L. (1990) *Nucleic Acids Res.*, **18**, 4917.
- Featherstone, C. and Russell, P. (1991) *Nature*, **349**, 808–811.
- Feinberg, A.P. and Vogelstein, B. (1983) *Anal. Biochem.*, **1**, 6–13.
- Fischer, G., Wittmann-Liebold, B., Lang, K., Keifhaber, T. and Schmid, F.X. (1989) *Nature*, **337**, 476–478.
- Foor, F., Parent, S.A., Morin, N., Dahl, A.M., Ramadan, N., Chrebet, G., Bostian, K.A. and Nielsen, J.B. (1992) *Nature*, **360**, 682–684.
- Freskgard, P.-O., Bergenhem, N., Jonsson, B.-H., Svensson, M. and Carlsson, U. (1992) *Science*, **258**, 466–468.
- Friedman, J. and Weissman, I. (1991) *Cell*, **66**, 799–806.
- Galat, A. (1993) *Eur. J. Biochem.*, **216**, 689–707.
- Goebel, M. and Yanagida, M. (1991) *Trends Biochem. Sci.*, **16**, 173–177.
- Gould, K.L. and Nurse, P. (1989) *Nature*, **342**, 39–45.
- Gutz, H., Heslot, H., Leupold, U. and Loprieno, N. (1974) In King, R.C. (ed.), *Handbook of Genetics, Vol. 1. Schizosaccharomyces pombe*. Plenum Publishing Corporation, New York, pp. 395–446.
- Handschumacher, R.E., Harding, M.W., Rice, J., Drugge, R.J. and Speicher, D.W. (1984) *Science*, **226**, 544–546.
- Harding, M.W., Handschumacher, R.E. and Speicher, D.W. (1986) *J. Biol. Chem.*, **261**, 8547–8555.
- High, K.P., Joiner, K.A. and Handschumacher, R.E. (1994) *J. Biol. Chem.*, **269**, 9105–9112.
- Hirano, T., Kinoshita, N., Morikawa, K. and Yanagida, M. (1990) *Cell*, **60**, 319–328.
- Hoffman, K. and Handschumacher, R.E. (1995) *Biochem. J.*, **307**, 5–8.
- Kallen, J., Spitzfaden, C., Mauro, G.M., Zurini, M., Wider, G., Widmer, H., Wüthrich, K. and Walkinshaw, M.D. (1991) *Nature*, **353**, 276–279.
- Kaufner, N., Simanis, V. and Nurse, P. (1985) *Nature*, **318**, 78–80.
- Kieffer, L.J., Thalhammer, T. and Handschumacher, R.E. (1992) *J. Biol. Chem.*, **267**, 5503–5507.
- Kieffer, L.J., Seng, T.W., Wei, L., Osterman, D.G., Handschumacher, R.E. and Bayney, R.M. (1993) *J. Biol. Chem.*, **268**, 12303–12310.
- Koser, P.L., Livi, G.P., Levy, M.A., Rosenberg, M. and Bergsma, D.J. (1990) *Gene*, **96**, 189–195.
- Koser, P.L. et al. (1991) *Gene*, **108**, 74–80.
- Lamb, J.R., Michaud, W.A., Sikorski, R.S. and Heiter, P.A. (1994) *EMBO J.*, **13**, 4321–4328.
- Lang, K., Schmid, F.X. and Fischer, G. (1987) *Nature*, **329**, 268–270.
- Lebeau, M.-C., Massol, N., Herrick, J., Faber, L.E., Renoir, J.M., Radanyi, C. and Baulieu, E.-E. (1992) *J. Biol. Chem.*, **267**, 4281–4284.
- Liu, J., Farmer, J.D., Jr, Lane, W.S., Friedman, J., Weissman, I. and Schreiber, S.L. (1991a) *Cell*, **66**, 807–815.
- Liu, J., Chen, C.-M. and Walsh, C.T. (1991b) *Biochemistry*, **30**, 2306–2310.
- Luan, S., Li, W., Rusnak, F., Assmann, S.M. and Schreiber, S.L. (1993) *Proc. Natl Acad. Sci. USA*, **90**, 2202–2206.
- Luan, S., Lane, W.S. and Schreiber, S.L. (1994) *Plant Cell*, **6**, 885–892.
- Lundgren, K., Walworth, N., Booher, R., Dembski, M., Kirschner, M. and Beach, D. (1991) *Cell*, **64**, 1111–1122.
- Maundrell, K. (1990) *J. Biol. Chem.*, **265**, 10857–10864.
- McLaughlin, M.M. et al. (1992) *Gene*, **111**, 85–92.
- Millar, J.B.A., McGowan, C.H., Lenaers, G., Jones, R. and Russell, P. (1991) *EMBO J.*, **10**, 4301–4309.
- Millar, J.B.A., Lenaers, G. and Russell, P. (1992) *EMBO J.*, **11**, 4933–4941.
- Molz, L., Booher, R., Young, P. and Beach, D. (1989) *Genetics*, **122**, 773–782.
- Moreno, S., Hayles, J. and Nurse, P. (1989) *Cell*, **58**, 361–372.
- Moreno, S., Klar, A. and Nurse, P. (1991) *Methods Enzymol.*, **194**, 795–823.
- Nurse, P. (1990) *Nature*, **344**, 503–508.
- Ogden, J.E. and Fantes, P.A. (1986) *Curr. Genet.*, **10**, 509–514.
- Ondek, B., Hardy, R.W., Baker, E.K., Stamnes, M.A., Shieh, B.-H. and Zuker, C.S. (1992) *J. Biol. Chem.*, **267**, 16460–16466.
- Parker, L.L., Atherton-Fessler, S., Lee, M.S., Ogg, S., Falk, J.L., Swenson, K.I. and Pivnicia-Worms, H. (1991) *EMBO J.*, **10**, 1255–1263.
- Perisic, O., Xiao, H. and Lis, J.T. (1989) *Cell*, **59**, 797–806.
- Polanshek, M.M. (1977) *J. Cell Sci.*, **23**, 1–23.
- Pratt, W.B. (1993) *J. Biol. Chem.*, **268**, 21455–21458.
- Radanyi, C., Chambraud, B. and Baulieu, E.E. (1994) *Proc. Natl Acad. Sci. USA*, **91**, 11197–11201.
- Ratajczak, T., Carrello, A., Mark, P.J., Warner, B.J., Simpson, R.J., Moritz, R.L. and House, A.K. (1993) *J. Biol. Chem.*, **268**, 13187–13192.
- Rothstein, R.J. (1983) *Methods Enzymol.*, **101**, 202–211.
- Sanchez, E.R. (1990) *J. Biol. Chem.*, **265**, 22067–22070.
- Sanger, F., Nicklen, S. and Coulson, A.R. (1977) *Proc. Natl Acad. Sci. USA*, **74**, 5463–5467.
- Shiozaki, K., Akhavan-Niaki, H., McGowan, C.H. and Russell, P. (1994) *Mol. Cell. Biol.*, **14**, 3742–3751.
- Sikorski, R.S., Boguski, M.S., Goebel, M. and Heiter, P. (1990) *Cell*, **60**, 307–317.
- Smith, B.J. and Yaffe, M.P. (1991) *Mol. Cell. Biol.*, **11**, 2647–2655.
- Stamnes, M.A., Rutherford, S.L. and Zuker, C.S. (1992) *Trends Cell Biol.*, **2**, 272–276.
- Sykes, K., Gething, M.-J. and Sambrook, J. (1993) *Proc. Natl Acad. Sci. USA*, **90**, 5853–5857.
- Tai, P.K.K., Maeda, Y., Nakao, K., Wakim, N.G., Duhring, J.L. and Faber, L.E. (1986) *Biochemistry*, **25**, 5269–5275.
- Tai, P.K.K., Albers, M.W., Chang, H., Faber, L.E. and Schreiber, S.L. (1992) *Science*, **256**, 1315–1318.
- Takahashi, N., Hayano, T. and Suzuki, M. (1989) *Nature*, **337**, 473–475.
- Thériault, Y., Logan, T.M., Meadows, R., Yu, L., Olejniczak, E.T., Holzman, T.F., Simmer, R.L. and Fesik, S.W. (1993) *Nature*, **361**, 88–91.
- Vieira, J. and Messing, J. (1987) *Gene*, **19**, 259–268.
- Warbrick, E. and Fantes, P.A. (1991) *EMBO J.*, **10**, 4291–4299.
- Warbrick, E. and Fantes, P.A. (1992) *Mol. Gen. Genet.*, **232**, 440–446.
- Yem, A.W., Tomasselli, A.G., Heinrich, R.L., Zurcher-Neely, H., Ruff, V.A., Johnson, R.A. and Deibel, M.R. (1992) *J. Biol. Chem.*, **267**, 2868–2871.
- Yoshida, T., Toda, T. and Yanagida, M. (1994) *J. Cell Sci.*, **107**, 1725–1735.

Received on November 28, 1994; revised on October 4, 1995